{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124583","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.810126+00:00","generated_at":"2026-05-30T02:08:40.921364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251","bullets":["Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.","FDA cleared IND for DYNE-101 in DM1; Phase 1/2 ACHIEVE trial fully enrolled through 6.8 mg/kg Q8W cohort (56 participants).","New ACHIEVE data (splicing, vHOT, functional measures) expected early January 2025; pursuing accelerated approval using splicing surrogate.","Enrolling 20 mg/kg Q4W registrational cohort (n=32) in DELIVER trial for DMD exon 51; seeks accelerated approval based on dystrophin.","Cash $723.7M at Sept 30, 2024; expected to fund operations at least into H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124583","json":"https://secwatch.observer/filing/0000950170-24-124583.json","markdown":"https://secwatch.observer/filing/0000950170-24-124583.md","text":"https://secwatch.observer/filing/0000950170-24-124583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/0000950170-24-124583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/dyn-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:08:40.921364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}